Business Description
Suven Pharmaceuticals Ltd
ISIN : INE03QK01018
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 12.69 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.14 | |||||
Interest Coverage | 47.14 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 48.44 | |||||
Beneish M-Score | -2.09 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 2.4 | |||||
3-Year EBITDA Growth Rate | -2.7 | |||||
3-Year EPS without NRI Growth Rate | -5.8 | |||||
3-Year FCF Growth Rate | 4.1 | |||||
3-Year Book Growth Rate | 20.2 | |||||
Future 3-5Y Total Revenue Growth Rate | 5.47 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 32.45 | |||||
9-Day RSI | 37.75 | |||||
14-Day RSI | 41.43 | |||||
6-1 Month Momentum % | -0.2 | |||||
12-1 Month Momentum % | 38.16 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 11.82 | |||||
Quick Ratio | 9.65 | |||||
Cash Ratio | 7.72 | |||||
Days Inventory | 221.21 | |||||
Days Sales Outstanding | 44.15 | |||||
Days Payable | 40.72 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | 0.15 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 57.34 | |||||
Operating Margin % | 33.41 | |||||
Net Margin % | 28.56 | |||||
FCF Margin % | 29.17 | |||||
ROE % | 15.75 | |||||
ROA % | 14.21 | |||||
ROIC % | 18.76 | |||||
ROC (Joel Greenblatt) % | 35.26 | |||||
ROCE % | 20.79 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 52.73 | |||||
PE Ratio without NRI | 52.73 | |||||
Price-to-Owner-Earnings | 53.06 | |||||
PEG Ratio | 2.65 | |||||
PS Ratio | 15.06 | |||||
PB Ratio | 7.73 | |||||
Price-to-Tangible-Book | 7.97 | |||||
Price-to-Free-Cash-Flow | 51.67 | |||||
Price-to-Operating-Cash-Flow | 44.2 | |||||
EV-to-EBIT | 36.53 | |||||
EV-to-EBITDA | 32.27 | |||||
EV-to-Forward-EBITDA | 18.65 | |||||
EV-to-Revenue | 14.35 | |||||
EV-to-Forward-Revenue | 7.89 | |||||
EV-to-FCF | 49.21 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.65 | |||||
Price-to-Graham-Number | 4.32 | |||||
Price-to-Net-Current-Asset-Value | 14.96 | |||||
Price-to-Net-Cash | 25.51 | |||||
Earnings Yield (Greenblatt) % | 2.74 | |||||
FCF Yield % | 1.93 | |||||
Forward Rate of Return (Yacktman) % | 21.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Suven Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ₹) | 10,513.537 | ||
EPS (TTM) (₹) | 11.81 | ||
Beta | 0.8 | ||
Volatility % | 23.85 | ||
14-Day RSI | 41.43 | ||
14-Day ATR (₹) | 21.378073 | ||
20-Day SMA (₹) | 646.0475 | ||
12-1 Month Momentum % | 38.16 | ||
52-Week Range (₹) | 427.05 - 767 | ||
Shares Outstanding (Mil) | 254.56 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Suven Pharmaceuticals Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Suven Pharmaceuticals Ltd Stock Events
Event | Date | Price(₹) | ||
---|---|---|---|---|
No Event Data |
Suven Pharmaceuticals Ltd Frequently Asked Questions
What is Suven Pharmaceuticals Ltd(BOM:543064)'s stock price today?
When is next earnings date of Suven Pharmaceuticals Ltd(BOM:543064)?
Does Suven Pharmaceuticals Ltd(BOM:543064) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |